Single dose tocilizumab for COVID‐19 associated cytokine storm syndrome: Less is more
British Journal of Clinical Pharmacology · 2025-04 · 91 (4) · 938-946
DOI: 10.1111/bcp.15690 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 24.02.2023. Verfasst von Niels W Boone und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Pharmacology and Toxicology, Zuyderland Medical Centre, Heerlen, The Netherlands. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Cytokine Release Syndrome, COVID-19 Drug Treatment. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
Aims
We aim to evaluate the clinical pharmacokinetics of a single dose interleukin‐6 (IL‐6) antibody tocilizumab (TCZ) in methylprednisolone (MP)‐treated COVID‐19 patients with cytokine storm syndrome (CSS).
Methods
MP pre‐treated patients with COVID‐19‐associated CSS, defined as at least two elevations of C‐reactive protein (CRP) >100 mg/L, ferritin >900 μg/L or D‐dimers >1500 μg/L, received intravenous TCZ (8 mg/kg, max. 800 mg) upon clinical deterioration. A nonlinear‐mixed effects model was developed based on TCZ serum concentrations and dosing information. Population pharmacokinetic parameters were estimated and concentration–time profiles were plotted against individual predicted values. Fixed dose simulations were subsequently performed based on the final model.
Results
In total 40 patients (mean [SD] age: 62 [12] years, 20% female, body weight: 87 [17] kg) with COVID‐19 induced CSS were evaluated on pharmacokinetics and laboratory parameters. A biphasic elimination of TCZ serum concentration was described by a homogeneous population pharmacokinetic model. Serum TCZ concentrations above the 1 μg/L target saturation threshold were covered for 16 days in all evaluated patients treated with a single dose of 8 mg/kg. In a simulation with TCZ 400 mg fixed dose, this condition of full IL‐6 receptor occupancy at minimum serum concentration was also met.
Conclusions
A single dose (8 mg/kg, max. 800 mg) is sufficient to cover a period of 16 days of IL‐6‐mediated hyperinflammation in COVID‐19‐induced CSS in MP‐treated patients. Based on body weight PK simulations, a fixed‐dose tocilizumab of 400 mg should be considered to prevent overtreatment, future drug shortage and unnecessary drug expenditure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, Pharmacology and Toxicology, Zuyderland Medical Centre, Heerlen, The Netherlands.
- Department of Clinical Pharmacy and Toxicology, Leiden University Medical Centre, Leiden, The Netherlands.
- Department of Rheumatology, Zuyderland Medical Centre, Heerlen, The Netherlands.
- Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.
- Department of Pulmonology, Zuyderland Medical Centre, Heerlen, The Netherlands.
- Department of Respiratory Medicine, Maastricht University Medical Centre, Maastricht, The Netherlands.
ORCID-Profile: Niels W Boone
Zitieren
APA
Boone, N. W., Moes, D. J. A. R., Ramiro, S., Mostard, R. L. M., Magro-Checa, C., van Dongen, C. M. P., Gronenschild, M., van Haren, E., Buijs, J., de Vries, A., Peeters, R., Landewé, R. B. M., & Wong, D. R. (2025). Single dose tocilizumab for COVID‐19 associated cytokine storm syndrome: Less is more. British Journal of Clinical Pharmacology, 91(4), 938-946. https://doi.org/10.1111/bcp.15690
Vancouver
Boone NW, Moes DJAR, Ramiro S, Mostard RLM, Magro-Checa C, van Dongen CMP, et al. Single dose tocilizumab for COVID‐19 associated cytokine storm syndrome: Less is more. British Journal of Clinical Pharmacology. 2025;91(4):938-946. doi:10.1111/bcp.15690
BibTeX
@article{Boone2025,
author = {Boone, Niels W and Moes, Dirk Jan A R and Ramiro, Sofia and Mostard, Remy L M and Magro-Checa, Cesar and van Dongen, Christel M P and Gronenschild, Michiel and van Haren, Eric and Buijs, Jacqueline and de Vries, Annick and Peeters, Ralph and Landewé, Robert B M and Wong, Dennis R},
title = {Single dose tocilizumab for COVID‐19 associated cytokine storm syndrome: Less is more},
journal = {British Journal of Clinical Pharmacology},
year = {2025},
volume = {91},
number = {4},
pages = {938--946},
doi = {10.1111/bcp.15690}
}
EUVIMED